Ultrasound vs. MRI: which spots hidden liver cancer better?
NCT ID NCT06184152
First seen Jul 02, 2026 · Last updated Jul 02, 2026
Summary
This study compares two imaging methods—contrast-enhanced ultrasound and abbreviated MRI—to see which is better at detecting early-stage liver cancer (HCC) in people with suspicious but not yet cancerous liver nodules. Researchers will enroll 600 adults with cirrhosis and indeterminate liver nodules at three medical centers. The goal is to find the most accurate and practical test for early detection.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
contrast-enhanced ultrasound (CEUS) and abbreviated MRI (AMRI)
What this could lead to
If one method proves more accurate, it could become the preferred way to detect early liver cancer, potentially catching more cases sooner.
What could go wrong
This is a diagnostic comparison study, not a treatment trial. Results may show no clear winner, and findings may not apply to all patients or settings.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- AWT020 for Advanced Cancers: Phase 1 Trial NCT06839105
- Liver Fibrosis in HIV-HBV Patients: NCT02344680
- 68Ga-FAPI-46 PET Imaging in Cancer Patients (NCT07118176)
- Liver Cancer Navigation Trial NCT06260943
- Deep Multi-Omics Study in Liver Cancer (NCT05516628)
- PRIME-HCC: Ipilimumab & Nivolumab Before Liver S NCT03682276
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Michigan
RECRUITINGAnn Arbor, Michigan, 48109, United States
Contact Email: •••••@•••••
-
University of Texas Southwestern Medical Center
RECRUITINGDallas, Texas, 75390, United States
Contact
Contact Email: •••••@•••••
Contact Email: •••••@•••••